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ABSTRACT The pathogenic features of melanomas include growth and 
amplification of atypical melanocytes associated with several features 
(self-sufficiency of growth factors, insensitivity to growth inhibitors, 
evasion of cellular apoptosis, limitless replicative potential, sustained 
angiogenesis, tissue invasion, and metastasis). These melanoma patho-
genic events can be triggered by activating oncogenes or inactivating 
tumor-suppressor genes by means of molecular mechanisms such as 
dotted mutations, deletions, and translocations or epigenetic mecha-
nisms such as microRNA expression and promoter methylation. In 
melanomas, an analysis of the gene aberrations in the genome has led 
to the discovery of the complex interaction of signaling pathways. Pro-
gression of melanomas also involves genetic instability and selective 
growth of cells with favorable mutations. Additional factors include 
genetic predisposition, mutagenesis, and suppressed host immune re-
sponse. Some of the most important signaling pathways involved in the 
pathogenesis of melanoma are the MAPK, PI3K/PTEN/AKT, and MITF 
signaling pathways. Obtaining insight into the biology of melanocytes 
and pathogenesis of melanomas is important for the development of a 
targeted therapy (such as vemurafenib, dabrafenib, trametinib) as well 
as the immunotherapy (e.g. pembrolizumab, nivolumab, ipilimumab), 
which has enabled a substantial breakthrough in the treatment of pa-
tients with melanoma.
KEY WORDS: melanoma, pathogenesis, signaling pathways, mutations, 
targeted therapy, immunotherapy 
INTRODUCTION
A melanoma develops through malignant trans-
formation of melanocytes, the cells producing the 
pigment melanin (1,2). The origin of melanocytes 
is associated with the fetal period and the melano-
cyte precursors which are produced in the neural 
ridge and which migrate to various localizations in 
the body during fetal development (including the 
skin, meningeal coverings, mucous membrane, the 
upper part of esophagus, and the eyes). This is why 
a melanoma can develop by malignant transforma-
tion of melanocytes in any of these places, but it most 
frequently develops in the skin – specifically, the hair 
follicles in the skin – where it develops from mela-
nocytes on the dermal-epidermal junction (3,4). The 
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pathogenic features of melanomas are associated 
with their growth and with amplification of atypical 
melanocytes. Several features have been observed: 
self-sufficiency of growth factors, insensitivity to 
growth inhibitors, evasion of cellular apoptosis, limit-
less replicative potential, sustained angiogenesis, tis-
sue invasion, and metastasis (5-7). These pathogenic 
events can be triggered by activating oncogenes or 
inactivating tumor-suppressor genes by means of 
molecular mechanisms such as dotted mutations, 
deletions, and translocations or epigenetic mecha-
nisms such as microRNA expression and promoter 
methylation. Analysis of the aberrations of genes in 
the genome has led to the discovery of the complex 
interaction of signaling pathways in melanomas (2). 
Progression of melanomas also involves genetic in-
stability and selective growth of cells with favorable 
mutations. Additional factors include genetic predis-
position, mutagenesis, and suppressed host immune 
response (2,7). Obtaining insight into the biology of 
melanocytes and the pathogenesis of melanoma is 
important for the design and development of anti-
cancer therapy (8,9).
RISK FACTORS IN MELANOMA DEVELOP-
MENT 
Environmental and genetic factors are involved in 
the pathogenesis of melanomas. The environmental 
factors include UV radiation, burns suffered early in 
life, physical features such as blonde or red hair, green 
or blue eyes, presence of multiple (>100) melanocytic 
nevi, five or more atypical nevi, and fair skin, although 
melanomas can also develop in persons with dark-
pigmented skin, as acral or mucosal melanomas, etc. 
(10,11). 
Melanomas of the trunk and limb skin are con-
nected with intermittent exposure to UV radiation 
and frequent BRAF (50%) and NRAS (20%) mutations. 
On the other hand, lower rates of BRAF mutations (5-
20%) and higher rates of KIT mutations (5-10%) have 
been demonstrated in mucosal and acral lentiginous 
melanomas (11).
Genetic factors are particularly important for the 
pathogenesis of melanomas (sporadic and family mel-
anomas). Genetic factor analysis has shown that it is 
the sporadic melanomas that account for most of the 
melanomas (90% of them). These are the melanomas 
which are not familial, their most marked mutation 
being BRAF (V600E) (1). On the other hand, familial 
melanomas account for only 10% of melanomas. Fa-
milial melanomas are mostly associated with the dys-
regulation of cell cycle regulators. Tumor suppressor 
gene cyclin-dependent kinase inhibitor 2A (CDKN2A) 
which encodes p16INK4A and p14 ARF proteins has 
been identified as a main high-risk gene for melano-
ma (10,12,13). It has been established that p16INK4α 
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regulates the transition from G1 to S phase of the cell 
cycle, functioning as a CDK inhibitor and blocking the 
phosphorylation and inactivation of the Rb protein at 
the same time, which is the key control point in the 
cell cycle. On the other hand, p14ARF also acts anti-
proliferatively and inhibits the disintegration of the 
p53 tumor suppressor. The normal expression of p53 
puts a stop to the cell cycle in G2/M phase or induces 
the programmed cell death (apoptosis) (e.g. as a re-
sponse to DNA damage caused by UV radiation) (1).
RELEVANT SIGNALING PATHWAYS IN-
VOLVED IN MELANOMA PATHOGENESIS
The MAPK pathway 
The MAPK signal pathway (mitogen-activated 
protein kinase cascade) regulates the cellular pro-
liferation, growth, and migration and is activated in 
almost all melanomas. The MAPK pathway activates 
normally as well, but in case of melanoma the path-
way becomes increasingly activated so the activation 
becomes excessive (2). The activation of the MAPK 
pathway takes place when a growth factor binds with 
a tyrosine kinase receptor (Figure 1). The stimulation 
of the receptor triggers activation of the members of 
RAS family – the monomer G proteins causing cas-
cade activation of serine/threonine kinases which in 
turn lead to activation of ERK (also known as MAPK). 
This ERK is a serine/threonine kinase that activates 
the transcription factors, thus intensifying the tran-
scription of the genes involved in cellular growth, 
proliferation, and migration. The crucial role of this 
pathway is emphasized by the fact that either NRAS 
or BRAF are mutated in approx. 80% of all skin mela-
noma or melanocytic nevi (2). The aberrations lead-
ing to activation of the MAPK pathway in melanomas 
mostly include the activating mutations of the BRAF 
serine/threonine kinase (40-50%) and G protein NRAS 
(15-20%) (14).
Understanding of the MAPK signaling pathway 
has led to development of targeted therapy for a 
subset of patients with BRAF-activating mutations. 
Although BRAF inhibitors showed clinical activity, 
combination therapy with BRAF + MEK inhibitos (ve-
murafenib + cobimetinib, dabrafenib + trametinib) 
further improved outcomes of patients with meta-
static and resected BRAF mutated melanoma and has 
therefore become the standard of care in this subset 
of patients (15,16). 
BRAF
BRAF is a serine/threonine kinase which is activat-
ed directly via RAS and is markedly expressed in me-
lanocytes, neural tissue, testicles, and hematopoietic 
cells. It has been established that BRAF phosphory-
lates and activates MEK (a component of the signal-
ing pathway; also the kinase participating in that cas-
cade) which in turn activates the ERK by phosphory-
lation and stimulates the growth and transformation 
crucial for the pathogenesis of melanomas (10,16.)
The most frequent BRAF mutation (~70% of all 
BRAF mutations) is the transversion of thymidine into 
adenine (T → A), resulting in the substitution of valine 
into glutamate (V600E) and leading to constitutive 
activation of the kinase domain. These mutations in-
directly activate BRAF by disrupting the normal intra-
molecular interactions that keep BRAF inactive (14). 
BRAF (V600E) mutations are more often observed in 
melanomas in the persons intermittently exposed to 
the sun than in those with acral and mucosal mela-
nomas. Although BRAF mutations can be associated 
with exposure to the sun, the said transversion (T → 
A) is not classically associated with UV damage (10). 
Other substitutions are also possible, particularly of 
V600K mutations (accounting for ~20% of the BRAF 
mutations in a melanoma) which are more frequent 
in the melanomas in the persons who were chroni-
cally exposed to the sun. Furthermore, BRAF V600 
mutations constitute an early event in melanoma de-
velopment and are observed in most of the benign 
and dysplastic nevi (approx. 80%) (14). BRAF (V600E) 
mutation induces forming of a nevus, including the 
initial cellular proliferation followed by oncogene-in-
duced aging, most likely as part of the accumulation 
of p16 ink4A. Thus, a mutated BRAF was observed 
in only 10% of the melanomas in the radial growth 
phase and in 6% of in situ melanomas. Additionally, 
many nevi and primary melanomas are polyclonal 
(containing both wild-type BRAF and BRAF mutated 
cells). The metastatic melanomas, on the other hand, 
are not polyclonal (10). It was also observed that the 
BRAF V600E mutations were more frequent in women 
and that they correlated in inverse proportion with 
age (9). BRAF V600K, on the other hand, was the most 
common sub-type and its incidence increased with 
age (14).
RAS
The mutations leading to increased RAS activity 
in melanomas also promote cellular proliferation, but 
significantly more rarely than in other solid tumors 
(10). The somatic mutation of NRAS genes can trigger 
the constitutive activity of the NRAS protein (which 
then cannot be “excluded”), resulting in serial activa-
tion of the serine/threonine kinases that stimulate 
the course of the cellular cycle, cellular transforma-
tion, and survival of the cells. This cascade of events 
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can be mediated by an excessive expression and/or 
hyperactivation of various growth factor receptors 
(like c-Met, epidermal growth factor receptors – EGFR 
and KIT), as well as by the loss of function of the neu-
rofibromatosis type 1 (NF1) tumor suppressor gene 
that suppresses the NRAS signaling (9,17). These 
activating RAS mutations were observed in only 10-
20% of melanomas (mostly in amelanotic nodular 
sub-types), usually the NRAS. While BRAF mutations 
activate the MAPK signaling pathway only, the NRAS-
activating mutations simultaneously activate both 
MAPK and PI3K pathways (10,17).
It was established that NRAS and BRAF mutations 
almost never take place concomitantly, indicating 
that mutation of any one of them was sufficient for 
constitutive activation of the MAPK pathway (10). 
The activating BRAF mutations are more frequent (in 
70-80% of dysplastic nevi) and NRAS mutations are 
rare (in most of the congenital nevi). HRAS mutations, 
on the other hand, are associated with Spitz nevi. 
Alternatively, the dysregulation of the AMPK signal-
ing pathway in melanomas can be caused by an ex-
cessive expression or hyperactivation of the growth 
factor receptors (such as c-Met, KIT and epidermal 
growth fator receptor – EGFR) (10). 
c-KIT
c-KIT (tyrosine kinase receptor) and its ligand 
(stem cell factor) have an important role in the de-
velopment of melanocytes (16). c-KIT mutations thus 
cause insufficient pigmentation. The results of numer-
ous immunohistochemical studies indicate that the 
transition from a benign condition into a primary or 
metastatic melanoma is associated with the loss of c-
KIT expression. Additionally, the activating mutations 
and amplifications of KIT genes were observed in cu-
taneous melanomas in persons chronically exposed 
to sun and in acral melanomas (hands, feet, nail bed). 
The KIT mutations can activate numerous signaling 
pathways, particularly the PI3K-AKT pathway. The 
dotted mutations of the KIT gene correspond with 
those in gastrointestinal stromal tumors (GIST). The 
functional characteristic of these mutations turned 
out to be clinically significant because KIT inhibitors 
are clinically efficient in melanomas, but with a much 
lower clinical response rate (10-30%) when compared 
with GIST (> 70%) (14).
c-MET and HGF
Excessive expression of c-MET (another tyrosine 
kinase receptor) and its ligand HGF (hepatocyte 
growth factor) correlates with the progression of 
melanomas. It is known that c-MET controls numer-
ous biological functions (proliferation, survival, mo-
tility, and invasion); thus, tumors can develop and 
malignant cells can metastasize in the case of their 
dysregulation by means of aberrant c-MET activation. 
Importantly, c-MET (tyrosine kinase receptor) can be 
excessively active in the case of excessive secretion 
of its ligand HGF, produced by the cells of the tumor-
ous melanoma microenvironment. This paracrine ef-
fect causes the activation of the PI3K-AKT pathway 
in tumor cells and stimulates resistance to the MAPK 
inhibitors (14)
Other factors
Other factors include: neurofibromatosis type 1 
(NF1) tumor suppressor and negative RAS regulator, 
which are also important in this context. NF1 muta-
tions were identified in 5 out of 21 tumors without 
BRAF and NRAS mutations. In the context of BRAF 
(V600E), it was observed that NF1 dysregulates the 
MAPK and PI3K pathways, suppressing the develop-
ment and proliferation of melanomas. In some mela-
nomas, inactivating mutations of neurofibromatosis 
type 2 (NF2) tumor suppressor was observed; it was 
also found that germline mutations NF1 and NF2 were 
associated with the hereditary neurofibromatosis 
(10). Additionally, somatic mutations were identified 
in the downstream MAPK effectors such as MAP3K5, 
MAP3K9, MEK1, and MEK2, in melanomas (10).
PI3K/PTEN/AKT pathway (phosphati-
dylinositol 3-kinase pathway) 
PI3K-AKT is another important signaling pathway 
involved in the regulation of cellular survival, growth, 
and apoptosis (2). In carcinomas, this pathway can be 
activated genetically, by means of either activating 
mutations (e.g. PIK3CA, AKT1) or loss of functions of 
certain components of this pathway (e.g. PTEN). The 
PI3 kinases (phosphatidylinositol 3-kinases) (lipid ki-
nases) are activated directly (by activating the tyro-
sine kinase receptor) or indirectly (by means of RAS), 
causing phosphorylation of PIP2 into PIP3 and, sub-
sequently, phosphorylation of AKT (14). PTEN lipid 
phosphatase has an important role, as it antagoniz-
es this pathway by converting PIP3 back to PIP2 (1). 
Phosphorylation of AKT (serine/threonine protein 
kinase) leads to phosphorylation of the multiple ef-
fector proteins that regulate the cellular processes 
(proliferation, survival, motility, angiogenesis, and 
metabolism). It was observed that a large number of 
melanomas showed increased activation of the PI3K 
signaling, usually by inactivation (by mutation, dele-
tion, methylation of promoters) of the genes encod-
ing PTEN inhibitor (2).
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MITF signaling
The microphthalmia-associated transcription fac-
tor (MITF) is a transcription factor required for the dif-
ferentiation of melanocytes, which can promote malig-
nant behavior in some melanomas. The most frequent 
genetic alteration of MITF is amplification, which takes 
place in 15-20% of melanomas (more often in meta-
static melanomas) (18). It is believed that MITF occurs 
later in the melanoma progression and that it is associ-
ated with a lower 5-year survival rate (19). It was ob-
served that MITF increased the expression of the genes 
involved in the cell cycle progression, cellular prolifera-
tion, and cellular survival. It is a transcription factor for 
cellular cyclin kinases (CDK2), CDK inhibitors p16INK4a 
and p21 and antiapoptotic mitochondrial membrane 
protein BCL-2 (B-cell lymphoma 2) (20,21).
MITF expression is activated by the activation of 
the melanocortin 1-receptor (MC1R). The latter is acti-
vated by binding of melanocortin (ACTH, α-MSH) (2). 
Its activation triggers the activation of adenylate cy-
clase and creation of c-AMP, which in turn activates the 
protein kinase A (PKA). PKA then activates CREB (cAMP 
response-element binding protein), which works as a 
transcription factor and intensifies the expression of 
MITF (2).
MITF signaling is also closely connected with and 
regulated by MAPK signaling. Importantly, MITF can 
also act as an anti-proliferative transcription factor that 
induces the termination of the cell cycle. In this con-
nection, it was observed that a mutated oncogenic 
BRAF could regulate MITF expression, thus ensuring 
the levels of the proteins compatible with the prolif-
eration and survival of melanoma cells (2). In melano-
cytes, MITF expression takes place after MSH (mela-
nocyte-stimulating hormone) has bound with MC1R 
(melanocortin 1 receptor). In this process MITF targets 
the genes involved in the regulation of differentiation 
and pigmentation, proliferation, and survival.
OTHER FACTORS IMPORTANT FOR MELA-
NOMA PATHOGENESIS
Numerous cellular interactions are also important 
in pathogenesis, with adhesion molecules (cadherins, 
adherents) taking part in them. The immune system 
also plays a significant role in melanoma carcinogen-
esis. Important factors in antitumor immunity are both 
humoral and cell-mediated immune response. Cancer 
cells can modify the immunological response in order 
to survive with several mechanisms such as down-reg-
ulated or disabled antigen presentation, immunologic 
barriers within the tumor microenvironment, negative 
regulatory pathways targeting T-cells, and T-cell dys-
function (22,23). 
Cytotoxic T-lymphocyte-associated antigen 4 
(CTLA-4) and programmed cell death protein 1 (PD1) 
are two immune checkpoints who regulate immune 
homeostasis by inhibition of T-cell activation. Devel-
opment of monoclonal antibodies targeting immune 
checkpoints CTLA-4 (ipilimumab) and PD1 (nivolum-
ab, pembrolizumab) which remove the inhibition of T-
cell activation and restore T cell recognition has revo-
lutionized the treatment of this disease showing more 
durable responses and benefits in long-term survival 
and had become the standard of care in most patients 
with advanced and metastatic melanoma (16,24,25).
Combination of immune-checkpoints inhibitors 
with BRAF/MEK targeted therapies, radiotherapy, other 
immunotherapies such as Indoleamine 2, 3-dioxygen-
ase 1 (IDO 1) inhibitors, as well with an oncolytic herpes 
virus Talimogene laherparepvec (TVEC) are currently 
ongoing with the goal of further improving response 
and activity of immune-checkpoints inhibitors (26).
A distinguishing feature of malignant neoplasms is 
their ability to metastasize. Normally, melanocytes are 
connected to basal keratinocytes with cell-cell adhe-
sion molecules, such as transmembrane glycoprotein 
E-cadherin. Loss of E-cadherin and upregulation of N-
cadherin leads to detachment of the melanoma cells 
from the epidermis and promotes melanoma invasion. 
Phosphatase and tensin homolog (PTEN) has been 
suggested as a potential regulator in this process of 
cell adhesion (1,27).
CONCLUSION
Pathogenesis of melanoma is a very complex pro-
cess that includes a series of events and factors, ge-
netic mutations, enzymes, and numerous molecules. 
It should be noted that obtaining insight into the bi-
ology of melanocytes and pathogenesis of melano-
mas is important primarily for devising and develop-
ing targeted therapy and immunotherapy, which has 
enabled a substantial breakthrough in the treatment 
of patients with this disease.
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